This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Ariazi EA , Brailoiu E , Yerrum S , Shupp HA , Slifker MJ , Cunliffe HE , Black MA , Donato AL , Arterburn JB , Oprea TI , Prossnitz ER , Dun NJ , Jordan VC
The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells
Cancer Res. 2010 Feb 1;70(3) :1184-94
PMID: 20086172 PMCID: PMC2879282
AbstractThe G protein-coupled receptor GPR30 binds 17beta-estradiol (E(2)) yet differs from classic estrogen receptors (ERalpha and ERbeta). GPR30 can mediate E(2)-induced nongenomic signaling, but its role in ERalpha-positive breast cancer remains unclear. Gene expression microarray data from five cohorts comprising 1,250 breast carcinomas showed an association between increased GPR30 expression and ERalpha-positive status. We therefore examined GPR30 in estrogenic activities in ER-positive MCF-7 breast cancer cells using G-1 and diethylstilbestrol (DES), ligands that selectively activate GPR30 and ER, respectively, and small interfering RNAs. In expression studies, E(2) and DES, but not G-1, transiently downregulated both ER and GPR30, indicating that this was ER mediated. In Ca(2+) mobilization studies, GPR30, but not ERalpha, mediated E(2)-induced Ca(2+) responses because E(2), 4-hydroxytamoxifen (activates GPR30), and G-1, but not DES, elicited cytosolic Ca(2+) increases not only in MCF-7 cells but also in ER-negative SKBr3 cells. Additionally, in MCF-7 cells, GPR30 depletion blocked E(2)-induced and G-1-induced Ca(2+) mobilization, but ERalpha depletion did not. Interestingly, GPR30-coupled Ca(2+) responses were sustained and inositol triphosphate receptor mediated in ER-positive MCF-7 cells but transitory and ryanodine receptor mediated in ER-negative SKBr3 cells. Proliferation studies involving GPR30 depletion indicated that the role of GPR30 was to promote SKBr3 cell growth but reduce MCF-7 cell growth. Supporting this, G-1 profoundly inhibited MCF-7 cell growth, potentially via p53 and p21 induction. Further, flow cytometry showed that G-1 blocked MCF-7 cell cycle progression at the G(1) phase. Thus, GPR30 antagonizes growth of ERalpha-positive breast cancer and may represent a new target to combat this disease.
NotesAriazi, Eric A Brailoiu, Eugen Yerrum, Smitha Shupp, Heather A Slifker, Michael J Cunliffe, Heather E Black, Michael A Donato, Anne L Arterburn, Jeffrey B Oprea, Tudor I Prossnitz, Eric R Dun, Nae J Jordan, V Craig CA116662/CA/NCI NIH HHS/United States CA118100/CA/NCI NIH HHS/United States CA127731/CA/NCI NIH HHS/United States HL090804/HL/NHLBI NIH HHS/United States HL090804-01A2S109/HL/NHLBI NIH HHS/United States HL51314/HL/NHLBI NIH HHS/United States NS18710/NS/NINDS NIH HHS/United States P30CA006927/CA/NCI NIH HHS/United States U54MH084690/MH/NIMH NIH HHS/United States Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. United States Cancer research Cancer Res. 2010 Feb 1;70(3):1184-94. Epub 2010 Jan 19.